Press release
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% - Adipose
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\n- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%\n\n\n- Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates\n\n\n- Improved Hepatic Dimer Platform Achieves Equivalent or Better Knockdown of Two Target Genes with Longer Duration than Monomer Mixture in Non-human Primates\n\n\n- TRiM™ Platform Now has Potential to Address Multiple Cell Types Including Liver, Solid Tumors, Lung, Central Nervous System, Skeletal Muscle, and Adipose\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m. ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.\n\n\nA webcast link may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website and the presentation materials will be posted following conclusion of the event.\n\n\nChristopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “In 2017 we had optimized the TRiM™ platform for hepatocyte delivery, but we had yet to advance any candidates into clinical studies. By the end of 2023, just 6 years later, we expect to have advanced 18 drug candidates into clinical studies addressing multiple cell types, including liver, solid tumor, pulmonary, CNS, and skeletal muscle, with three candidates currently in Phase 3 studies. This has been an enormously productive period for Arrowhead, which we intend to continue as we make progress towards our 20 in 25 goal to have 20 clinical stage or marketed products that utilize the TRiM™ platform in the year 2025. We are excited about the progress we’ve achieved to date and by what lies ahead, as we continue to expand the platform into systemic delivery to the CNS that crosses the blood brain barrier, delivery to adipose tissue, and delivery of dimers that can knock down two separate genes.”\n\n\nThe R&D Day will feature presentations by three key opinion leaders: Michael Benatar, M.D., Ph.D. (University of Miami Miller School of Medicine), who wil...